The 20 Best Breast Cancer Doctors Near Me

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of Breast Cancer. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer. Dr. Tolaney is board certified in Medical Oncology.

Dr. Lin is a medical oncologist specializing in the care of patients with all stages of breast cancer. Her research focuses upon improving the outcomes of people living with metastatic breast cancer, including a particular focus on the challenge of breast cancer brain metastases. She has led multiple clinical trials which have led to new treatment options for patients with breast cancer that has metastasized to the brain. Dr. Lin received her MD from Harvard Medical School in 1999. She completed her residency in internal medicine at Brigham and Women's Hospital and went on to complete fellowships in medical oncology and hematology at Dana-Farber. In 2005, she joined the staff of Brigham and Women's and Dana-Farber, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Dr. Lin is rated as an Elite provider by MediFind in the treatment of Breast Cancer. She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Brain Tumor, and Inflammatory Breast Cancer. Dr. Lin is board certified in Medical Oncology.

Dr. O'Shaughnessy is a Medical Oncologist that focuses on breast cancer prevention and treatment. She founded The School of Breast Oncology, a program providing a curriculum-based program focused exclusively on breast cancer clinical management. Dr. O'Shaughnessy attended medical school at Yale University School of Medicine in New Haven, CT. She then completed her Internal Medicine residency at Massachusetts General Hospital in Boston, MA and a Medical Oncology fellowship at National Cancer Institute in Bethesda, MD. She is co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center and a member of the Scientific Advisory Board for US Oncology Research Network. Dr. O'shaughnessy is rated as an Elite provider by MediFind in the treatment of Breast Cancer. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Inflammatory Breast Cancer, and Tissue Biopsy. Dr. O'shaughnessy is board certified in Medical Oncology- American Board Of Internal Med/Medical Oncology, Internal Medicine- American Board Of Internal Med, Internal Medicine- American Board Of Internal Medicine, and Medical Oncology- American Board Of Internal Medicine.

Kevin Kalinsky is an Oncologist practicing medicine in Atlanta, Georgia. Dr. Kalinsky is rated as an Elite provider by MediFind in the treatment of Breast Cancer. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Inflammatory Breast Cancer.

Adam M. Brufsky, MD, PhD, FACP, is professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine's Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women's Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; associate director for clinical investigations at UPMC Hillman Cancer Center; and codirector of the Comprehensive Breast Cancer Center.Dr. Brufsky is board-certified in internal medicine and medical oncology. He earned a medical and doctor of philosophy degrees from the University of Connecticut School of Medicine in Farmington, Conn.; completed a residency at Brigham and Women's Hospital, Harvard Medical School, and a fellowship at Dana-Farber Cancer Institute.Dr. Brufsky is a member of professional organizations, such as American Medical Association, Massachusetts Medical Society, American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, Allegheny County Medical Society, Pennsylvania Medical Society, and Pennsylvania Oncologic Society. An active researcher, Dr. Brufsky has numerous abstracts and research articles in leading journals, and is principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army - Breast Cancer Research Program. Dr. Brufsky is rated as an Elite provider by MediFind in the treatment of Breast Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Gastrostomy. Dr. Brufsky is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Brufsky is currently accepting new patients.

Nadine Tung is an Internal Medicine specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Tung is rated as an Elite provider by MediFind in the treatment of Breast Cancer. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Ovarian Cancer, HER-2 Positive Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT). Dr. Tung is board certified in American Board Of Internal Medicine.

My clinical practice if focused on the care of patients with breast cancer, particularly those diagnosed at a younger age and those with recurrence in the central nervous system. I am committed to the care of patients with breast cancer brain metastases, and I am honored to serve as the Medical Director of the Brain and Spine Metastases Program in the Duke Cancer Center. In this role, our multidisciplinary team provides well-coordinated care for patients with breast cancer and other solid tumor types that have metastasized to the central nervous system. In addition, I enjoy helping young women diagnosed with breast cancer navigate their treatment decisions to ensure both excellent medical care and attention to individual challenges, such as future fertility, sequelae of treatment on longer-term health, and impact on current and future relationships. When not working, I enjoy running, reading, and traveling with my family. Dr. Anders is rated as an Elite provider by MediFind in the treatment of Breast Cancer. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Brain Tumor, Triple-Negative Breast Cancer, and Metastatic Brain Tumor.

Dr. Partridge received her MD from Cornell University Medical College in 1995. She completed her residency in internal medicine at the Hospital of the University of Pennsylvania and went on to complete fellowships in medical oncology and hematology at DFCI, MGH and BWH. She also received an MPH from Harvard School of Public Health. She is a medical oncologist who cares for adults with breast cancer, with a particular focus on the unique needs of young patients with breast cancer. She also leads efforts to optimize cancer survivorship care and research at DFCI. She completed fellowships in Medical Oncology and Hematology at DFCI, Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Partridge is rated as an Elite provider by MediFind in the treatment of Breast Cancer. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, BRCA Positive Breast Cancer, Hormone Replacement Therapy (HRT), and Salpingo-Oophorectomy. Dr. Partridge is board certified in Medical Oncology.

William Gradishar is an Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 44 years. Dr. Gradishar is rated as an Elite provider by MediFind in the treatment of Breast Cancer. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and PIK3CA-Related Overgrowth Spectrum. Dr. Gradishar is board certified in American Board Of Internal Medicine - Internal Medicine (Certified).

Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine. Dr. Wolff is rated as an Elite provider by MediFind in the treatment of Breast Cancer. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer. Dr. Wolff is board certified in American Board Of Internal Medicine.

Hope Rugo is an Oncologist practicing medicine in San Francisco, California. Dr. Rugo is rated as an Elite provider by MediFind in the treatment of Breast Cancer. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Bone Marrow Aspiration, and Hormone Replacement Therapy (HRT).

Hironobu Sasano practices practicing medicine in Sendai, Japan. Sasano is rated as an Elite expert by MediFind in the treatment of Breast Cancer. They are also highly rated in 23 other conditions, according to our data. Their clinical expertise encompasses Adrenal Gland Adenoma, Hyperaldosteronism, Adrenal Cancer, Pancreaticoduodenectomy, and Mastectomy.

Giuseppe Curigliano practices practicing medicine in Milan, Italy. Mr. Curigliano is rated as an Elite expert by MediFind in the treatment of Breast Cancer. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Mastectomy, and Tissue Biopsy.

Nadia Harbeck practices practicing medicine in Koeln, Germany. Ms. Harbeck is rated as an Elite expert by MediFind in the treatment of Breast Cancer. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, Agranulocytosis, and Mastectomy.

Sibylle Loibl practices practicing medicine in Neu Isenburg, Germany. Ms. Loibl is rated as an Elite expert by MediFind in the treatment of Breast Cancer. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, Breast Cancer in Men, and Mastectomy.

Funda Meric is a General Surgeon and a Surgical Oncologist practicing medicine in Houston, Texas. Dr. Meric is rated as an Elite provider by MediFind in the treatment of Breast Cancer. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Breast Cancer, Cholangiocarcinoma (Bile Duct Cancer), Triple-Negative Breast Cancer, and Mastectomy.

Dr. Hershman is Witten Family Professor of Medicine, American Cancer Society Professor of Medicine and Epidemiology, chief of the division of hematology/oncology, and deputy director of the Herbert Irving Comprehensive Cancer Center at Columbia University. She completed her medical degree at the Albert Einstein College of Medicine, and completed her internal medicine and oncology fellowship training at Columbia University Medical Center, where she served as Chief Resident. During that time she completed a Master's degree in Biostatistics at the Mailman School of Public Health. She has developed nationally recognized expertise in breast cancer treatment, prevention, and survivorship.Dr. Hershman has also developed a comprehensive multidisciplinary program to study ways of improving cancer care delivery (CCD), reducing disparities and designing studies to improve the quality of life and quality of care in breast cancer survivors. She has received funding from the American Society of Clinical Oncology, American Cancer Society, Department of Defense, Breast Cancer Research Foundation, PCORI, and the National Cancer Institute. She currently has mentored numerous faculty members who have been granted mentored career development awards, and has received the Women Who Conquer Cancer Mentorship Award and the CUIMC Mentor of the Year Award. Dr. Hershman has published over 450 scientific articles and has received several awards including the highly prestigious Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology, the Advanced Medical Achievement Award from the Avon Foundation and a Giants in Cancer Care Award.She has several national leadership roles in oncology. As vice chair of the SWOG Cancer Research Network she oversees the NCI's Community Oncology Research Programs (NCORP) research portfolio, which includes prevention and epidemiology, cancer care delivery, symptom control and quality of life, and survivorship trials. Within ASCO she was selected to participate in the first Leadership Development Program and has been the Chair of the Grants Selection Committee, Chair of the ASCO Quality Care Symposium and has been a member of multiple committees and task-forces. She is on the editorial board for the Journal of Clinical Oncology and is an Associate Editor at the Journal of the National Cancer Institute. Dr. Hershman is rated as an Elite provider by MediFind in the treatment of Breast Cancer. She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Febrile Neutropenia, Inflammatory Breast Cancer, Vulvectomy, and Salpingo-Oophorectomy. Dr. Hershman is board certified in Internal Medicine and Medical Oncology. Dr. Hershman is currently accepting new patients.

Patrick Neven practices practicing medicine in Leuven, Belgium. Mr. Neven is rated as an Elite expert by MediFind in the treatment of Breast Cancer. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Mastectomy, and Oophorectomy.

Lee Schwartzberg is an Oncologist practicing medicine in Reno, Nevada. Dr. Schwartzberg is rated as an Elite provider by MediFind in the treatment of Breast Cancer. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Agranulocytosis, Febrile Neutropenia, Paget Disease of the Breast, and Tissue Biopsy.

Aditya Bardia is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Bardia is rated as an Elite provider by MediFind in the treatment of Breast Cancer. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, Agranulocytosis, and Tissue Biopsy.